Supplementary Methods, Figures S1-S8, Tables S1-S7 from Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia
This file contains Supplementary Methods describing the Pediatric Preclinical Testing Program (PPTP) scoring method. Supplementary Figure S1: Engraftment rates and organ infiltration of MLL-ALL xenografts. Supplementary Figure S2: Comparison of expression of specific genes between MLL-ALL and BCP-ALL xenografts. Supplementary Figure S3: Comparison of HOXA gene expression between MLL-ALL and BCP-ALL xenografts. Supplementary Figure S4: RG7112 induces caspase-dependent cell death in RS4;11 cells. Supplementary Figure S5: In vivo efficacy of RG7112 against MLL-ALL xenografts. Supplementary Figure S6: Effects of RG7112 on mouse weight and haematological parameters. Supplementary Figure S7: Immunoblots of spleen-derived cells from replicate mice showing the effects of RG7112 on MLL-14 xenograft cells. Supplementary Figure S8: Relationships between TP53 and MDM2 gene expression and in vivo responses of ALL xenografts to RG7112. Supplementary Table S1: Rates of serial engraftment of MLL-ALL xenografts. Supplementary Table S2: The top 100 genes that distinguish MLL-rearranged ALL xenografts from BCP-ALL xenografts. Supplementary Table S3: Statistical analysis of genes identified by Armstrong et al (2002) between MLL-ALL and BCP-ALL xenografts. Supplementary Table S4: Details of individual mouse responses to in vivo treatment with RG7112. Supplementary Table S5: In vitro Combination Indices of RG7112 with established drugs used to treat ALL. Supplementary Table S6: In vivo efficacy of RG7112 in combination with a VXL induction-type regimen. Supplementary Table S7: Details of individual mouse responses to in vivo treatment with RG7112 combined with VXL against MLL-ALL xenografts.